15.98

3.91% -0.65

After Hours: 15.98

Fortrea Holdings Inc (FTRE)

Overview News Price History Option Chain Financials Why FTRE Down? Discussions Forecast

Fortrea Holdings Inc stock is traded at $15.98, with a volume of 1.47M. It is down -3.91% in the last 24 hours and up +16.98% over the past month. Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

Previous Close:

$16.63

Open:

$16.67

24h Volume:

1.47M

Relative Volume:

1.11

Market Cap:

$1.51B

Revenue:

$2.71B

Net Income/Loss:

$-446.90M

P/E Ratio:

-3.2515

EPS:

-4.9146

Net Cash Flow:

$190.40M

1W Performance:

-5.33%

1M Performance:

+16.98%

6M Performance:

-0.06%

1Y Performance:

+175.99%

1-Day Range:

$15.90

$16.69

1-Week Range:

$15.90

$17.24

52-Week Range:

$4.355

$18.67

Fortrea Holdings Inc Stock (FTRE) Company Profile

Name

Fortrea Holdings Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

877-495-0816

Address

8 MOORE DRIVE, DURHAM

Employee

14,000

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

FTRE's Discussions on Twitter

Compare FTRE vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FTRE Fortrea Holdings Inc	15.98	1.57B	2.71B	-446.90M	190.40M	-4.9146
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Fortrea Holdings Inc Stock (FTRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-09-26	Upgrade	TD Cowen	Hold → Buy
Jan-08-26	Upgrade	Truist	Hold → Buy
Jan-06-26	Upgrade	Evercore ISI	In-line → Outperform
Dec-15-25	Upgrade	Barclays	Underweight → Equal Weight
Dec-11-25	Upgrade	Citigroup	Neutral → Buy
Aug-04-25	Upgrade	Robert W. Baird	Neutral → Outperform
May-02-25	Initiated	Truist	Hold
Apr-10-25	Downgrade	Barclays	Equal Weight → Underweight
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Dec-06-24	Downgrade	Robert W. Baird	Outperform → Neutral
Sep-25-24	Downgrade	Jefferies	Buy → Hold
Aug-08-24	Downgrade	Evercore ISI	Outperform → In-line
Jul-24-24	Resumed	Barclays	Equal Weight
Jun-06-24	Initiated	Goldman	Neutral
May-29-24	Initiated	TD Cowen	Hold
May-28-24	Initiated	Mizuho	Neutral
Mar-22-24	Initiated	Robert W. Baird	Neutral
Mar-06-24	Initiated	Deutsche Bank	Hold
Jan-05-24	Initiated	William Blair	Mkt Perform
Jan-04-24	Initiated	Jefferies	Buy
Dec-11-23	Upgrade	Citigroup	Neutral → Buy
Dec-01-23	Upgrade	Evercore ISI	In-line → Outperform
Nov-14-23	Upgrade	Barclays	Equal Weight → Overweight
Oct-19-23	Initiated	Citigroup	Neutral
Sep-14-23	Initiated	Evercore ISI	In-line
Aug-16-23	Initiated	Barclays	Equal Weight
Aug-07-23	Initiated	BofA Securities	Underperform

View All

Fortrea Holdings Inc Stock (FTRE) Latest News

Jun 12, 2026

Fortrea (FTRE) director boosts equity stake with RSU exercise and new 12,852-unit grant - Stock Titan

Jun 12, 2026

Fortrea (FTRE) director updates holdings after RSU vesting, tax withholding and new grant - Stock Titan

Jun 12, 2026

Fortrea (FTRE) director Pesicka settles 38,817 RSUs, gets 12,852 new - Stock Titan

Jun 12, 2026

Fortrea (FTRE) director Peter Neupert receives 12,852 RSU award - Stock Titan

Jun 12, 2026

Fortrea (FTRE) COO Morais reports open-market sale and updates holdings - Stock Titan

Jun 12, 2026